IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS

Authors

Jeffrey R. Willis (ORCID: https://orcid.org/0000-0002-6712-1144)
Kara Gibson (ORCID: https://orcid.org/0009-0001-9016-3481)
Gábor Deák (ORCID: https://orcid.org/0000-0002-7885-7624)
Peter D. Westenskow (ORCID: https://orcid.org/0000-0001-9841-6220)
Glenn Yiu (ORCID: https://orcid.org/0000-0003-3061-3310)
Rahul N. Khurana (ORCID: https://orcid.org/0000-0001-5198-1353)
T. H. Wang (ORCID: https://orcid.org/0000-0002-1640-9615)
Eric Nudleman (ORCID: https://orcid.org/0000-0002-9467-1563)
Glenn J. Jaffe (ORCID: https://orcid.org/0000-0003-2568-7892)
David T. Wong (ORCID: https://orcid.org/0000-0003-1376-845X)
Yuichiro Ogura (ORCID: https://orcid.org/0000-0003-0430-5330)
Ursula Schmidt-Erfurth (ORCID: https://orcid.org/0000-0002-9168-0894)

Institutions

Roche (Switzerland) (CH)
St. Michael's Hospital (CA)
Duke University (US)
UC San Diego Health System (US)
Nagoya City University (JP)
Roche (Canada) (CA)
St Michael’s Hospital (IE)
Roche (United Kingdom) (GB)
Retina Vitreous Associates of Florida (US)
Medical University of Vienna (AT)
University of California, Davis (US)

Publication Details

Journal: Retina
Published: 2025-07-16
DOI: https://doi.org/10.1097/iae.0000000000004572
Citations: 6
Primary Topic: Retinal Diseases and Treatments
Type: article
Field-Weighted Citation Impact: 10.24

Funders

F. Hoffmann-La Roche
Genentech

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS

Jeffrey R. Willis, Kara Gibson, Gábor Deák, Peter D. Westenskow et al.

Jul 16, 2025

6 citations

Retina

Retinal Diseases and Treatments

10.24

article

IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS

Jeffrey R. Willis, Kara Gibson, Gábor Deák, Peter D. Westenskow, Glenn Yiu, Rahul N. Khurana, T. H. Wang, Eric Nudleman, Glenn J. Jaffe, David T. Wong, Yuichiro Ogura, Ursula Schmidt-Erfurth

July 16, 2025article en

6 citations

Abstract

No abstract available for this paper.

RetinaVol. 45(11)

Roche (Switzerland) (CH), St. Michael's Hospital (CA), Duke University (US), UC San Diego Health System (US), Nagoya City University (JP), Roche (Canada) (CA), St Michael’s Hospital (IE), Roche (United Kingdom) (GB), Retina Vitreous Associates of Florida (US), Medical University of Vienna (AT), University of California, Davis (US)

F. Hoffmann-La Roche, Genentech

Peace, Justice and strong institutions

Openalex Percentile: Top 1%

Retinal Diseases and Treatments

10.24

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

IMPACT OF FARICIMAB VERSUS AFLIBERCEPT ON EPIRETINAL MEMBRANE FORMATION OVER 2 YEARS IN PATIENTS WITH DIABETIC MACULAR EDEMA IN THE PHASE 3 YOSEMITE AND RHINE TRIALS — Jeffrey R. Willis, Kara Gibson, et al. · Retina (2025) | TGRS Research Map | TGRS